Fetal Cell Receptors Repertoire
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 8, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Fetal Cell Receptors Repertoire," is looking to understand how certain cells from the fetus behave in postpartum women, especially those who have wounds like venous, diabetic, or sickle cell ulcers. Researchers will collect and analyze fetal cells from the blood of postpartum women who have these skin ulcers and compare them to healthy postpartum women who do not have ulcers. The main goal is to identify specific proteins, called chemokine receptors, that are more common in the fetal cells of women with wounds.
To be eligible for this study, participants must be adult women who have recently given birth, regardless of how many times they have been pregnant. They should either have a skin ulcer (like those mentioned) or be healthy volunteers of similar age without any ulcers. All participants will need to give their consent and may be asked to provide blood or saliva samples. It’s important to note that minors and individuals who are unable to make their own medical decisions cannot participate. This study aims to improve our understanding of healing processes in postpartum women and may help in developing better treatments for skin ulcers in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Common criteria :
- • Adult women,
- • Post-partum: having been pregnant for any length of time,
- • Having signed a free and informed consent form,
- • Primiparous or multiparous,
- • Affiliated to a health insurance
- Patients :
- • - Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer
- Control group patients :
- • Volunteers,
- • Age-matched,
- • Without skin ulcers.
- • There are no specific criteria for children.
- Exclusion Criteria:
- • Minors (for patients)
- • Under court protection, curatorship, guardianship (for patients)
- • Immunocompromised patients for any reason whatsoever
- • Refusal of consent
- • Refusal of blood and/or saliva samples for themselves or a member of their family
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, Ile De France, France
Patients applied
Trial Officials
Sélim ARACTINGI, MD, PHD
Study Director
Dermatology unit, Cochin Hospital - APHP
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported